Clinical trials: Social Phobia
Social Anxiety Disorder
Escitalopram in Patients With Social Anxiety Disorder
The purpose of this study is to evaluate the effect of escitalopram after 12 weeks of treatment in patients with Social Anxiety Disorder (SAD), to evaluate proportion of patients who respond to escitalopram during the treatment…
- Trial name
- NCT00902226
- Testing
- Escitalopram
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- H. Lundbeck A/S
Social Phobia, Social Anxiety Disorder
Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia
The purpose of this study is to determine the efficacy of PH94B, a new class of therapeutic compound, administered intranasally for the management of acute anxiety in patients diagnosed with generalized social phobia.
- Trial name
- PH94B-SAD (NCT01217788)
- Testing
- PH94B intranasal spray
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Pherin Pharmaceuticals, Inc.
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Social Anxiety Disorder
fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder
Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core…
- Trial name
- NCT00332046
- Testing
- GW679769
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Social Phobia
Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder
The purpose of this study is to look at the safety and effectiveness of an investigational drug (AV608) when used in subjects who have Social Anxiety Disorder.
- Trial name
- NCT00294346
- Testing
- AV608
- Where
- 15 sites in United States
- Volunteers
- 180 people
- Sponsor
- Avera Pharmaceuticals
Social Phobia
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder
This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.
- Trial name
- NCT00191022
- Testing
- LY686017, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 185 people
- Sponsor
- Eli Lilly and Company
Social Anxiety Disorder
Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder…
- Trial name
- NCT00238719
- Testing
- Venlafaxine ER
- Volunteers
- 293 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer